MedTrace Logo

A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA

NCT06535685 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-08-02

No results posted yet for this study

Summary

Efficacy and safety of Romiplostim in the treatment of refractory transfusion-dependent NSAA.

Conditions

  • Aplastic Anemia

Interventions

DRUG

Romiplostim

Enrolled patients will be given Romiplostim (20 µg/kg subcutaneously once a week) for a minimum of 3 months.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-02
Primary Completion
2025-03-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06535685 on ClinicalTrials.gov